← Leaderboards
Eunsil Hahm
Rush University Medical Center
$2,200,363
Attributed
$2,961,447
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $974.9K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,961,447 · 2
By mechanism
R01$2,961,447 · 2
Top collaborators
- Jochen Reiser3 shared
Most similar at Rush University Medical Center
Same institution · by research overlap
- Sumant Singh Chugh$16,868,252
- Lionel Claudius Clement$2,769,528
- Jian Zhang$9,988,086
- Camille Emilie Adeline Mace$994,136
- Harvey D Preisler$1,738,188
Others in their field
Other Emerging Leaders on “Signal Transduction”
- Yunda Huang · Fred Hutchinson Cancer Center$53,064,276
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Leonard Freedman · Leidos Biomedical Research, Inc.$32,575,497
- Bala Raja · Luminostics, Inc.$28,624,460
- Suzanne L Baker · University Of Pittsburgh At Pittsburgh$20,465,582
Research focus
Signal TransductionKidneyMolecularRenal Glomerular DiseaseKidney DiseasesNovel TherapeuticsIn VivoMediatingPathway InteractionsRenal FunctionPublishingTargeted TreatmentProteinuriaPathogenesisInjury To KidneyIn VitroFocal And Segmental GlomerulosclerosisGlioblastomaFoot ProcessGlomerular EndotheliumAnimalsCell TypeBindingHalf-Life
Grant awards (7)
Targeting bone marrow to treat renal disease$424,750
R01 · FY2025 · DK
Targeting bone marrow to treat renal disease$489,477
R01 · FY2024 · DK
The role of ICOSL in renal protection$339,035
R01 · FY2024 · DK · contact PI
Targeting bone marrow to treat renal disease$607,942
R01 · FY2023 · DK
The role of ICOSL in renal protection$366,978
R01 · FY2023 · DK · contact PI
The role of ICOSL in renal protection$366,978
R01 · FY2022 · DK · contact PI
The role of ICOSL in renal protection$366,287
R01 · FY2021 · DK · contact PI